GTR Test Accession:
Help
GTR000600646.1
CAP
Registered in GTR:
2022-10-27
View version history
GTR000600646.1,
registered in GTR:
2022-10-27
Last annual review date for the lab: 2022-11-01
Past due
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Pre-symptomatic;
Screening
Conditions (12):
Help
Gaucher disease;
Alpha mannosidosis type II;
Alpha-N-acetylgalactosaminidase deficiency type 1
more...
Analytes (2):
Help
Alpha-glucosidase;
Hexosaminidase A and B
Enzymes (3):
Help
Alpha-galactosidase;
Beta-glucocerebrosidase;
alpha-L-Fucosidase
Genes (19):
Help
Methods (3):
Help
Biochemical Genetics - Analyte: Gas chromatography–mass spectrometry (GC-MS); ...
Target population: Help
Not provided
Clinical validity:
Help
This panel should be performed in all individuals suspected of …
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Specimen Source:
Help
- Dried blood spot (DBS) card
- Peripheral (whole) blood
Who can order: Help
- Genetic Counselor
- Health Care Provider
- Licensed Dentist
- Licensed Physician
- Nurse Practitioner
- Physician Assistant
Contact Policy:
Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order:
Help
Test service:
Help
Clinical Testing/Confirmation of Mutations Identified Previously
Custom Deletion/Duplication Testing
Custom Sequence Analysis
Enzyme Analysis
Custom Deletion/Duplication Testing
Custom Sequence Analysis
Enzyme Analysis
Test development:
Help
Test developed by laboratory (no manufacturer test name)
Informed consent required:
Help
Decline to answer
Test strategy:
Help
Complete enzyme panel analysis for related diseases + automatic reflex to NGS genetic testing if an enzyme deficiency is identified.
Pre-test genetic counseling required:
Help
Decline to answer
Post-test genetic counseling required:
Help
Decline to answer
Recommended fields not provided:
Test Order Code,
Lab contact for this test
Conditions
Help
Total conditions: 12
Condition/Phenotype | Identifier |
---|
Test Targets
Analytes
Help
Total analytes: 2
Analyte | Associated Condition |
---|
Enzymes
Help
Total enzymes: 3
Enzyme | Associated Condition |
---|
Genes
Help
Total genes: 19
Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
---|
Methodology
Total methods: 3
Method Category
Help
Test method
Help
Instrument *
Analyte
Gas chromatography–mass spectrometry (GC-MS)
Deletion/duplication analysis
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Pre-symptomatic;
Screening
Clinical validity:
Help
This panel should be performed in all individuals suspected of having an overlapping clinical phenotype. Confirmation of a clinical diagnosis through genetic testing can allow for genetic counseling and may direct medical management. Genetic counseling can provide a patient and/or family with the natural history of the condition, identify at-risk …
View more
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS?
Help
The interpretation of a variation as a VUS is done according to the practice guidelines provided by the American College of Medical Genetics (ACMG; ACMG recommendations for standards for interpretation and reporting of sequence variations).
The interpretation of a variation as a VUS is done according to the practice guidelines provided by the American College of Medical Genetics (ACMG; ACMG recommendations for standards for interpretation and reporting of sequence variations).
Are family members with defined clinical status recruited to assess significance of VUS without charge?
Help
No.
No.
Will the lab re-contact the ordering physician if variant interpretation changes?
Help
Yes. In case of identification of mutation that can be present in non-affected family members, or after identification of highly specific genetic change, or in additional special situations we could contact the ordering again
Yes. In case of identification of mutation that can be present in non-affected family members, or after identification of highly specific genetic change, or in additional special situations we could contact the ordering again
Recommended fields not provided:
Clinical utility,
Target population,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Test Platform:
NimbleGen CGH 3-plex ISCA Plus Cytogenetic Array
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
CENTOGENE has established stringent quality criteria and validation processes for variants detected by NGS. Variants with low sequenci ng quality and/or unclear zyg osity are confirmed by orthogonal methods. Consequently, a specificity of > 99.9% for all reported variants is warranted. Mitochondrial variants are reported for heteroplasmy levels of 15% …
View more
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
Yes
Method used for proficiency testing: Help
Formal PT program
PT Provider: Help
American College of Medical Genetics / College of American Pathologists, ACMG/CAP
VUS:
Software used to interpret novel variations
Help
CentoMD®, ALAMUT, integrating other programs (Polyphen-2, Mutation Tester, Alignment, ExPASy, BLAST)
Laboratory's policy on reporting novel variations Help
Centogene has a common practice to report all variants found in genetic testing, including novel and previously reported variants. A number of criteria are used to support a variant as being potentially disease-causing, including segregation with disease status in other affected family members, absence from a control population, and location … View more
CentoMD®, ALAMUT, integrating other programs (Polyphen-2, Mutation Tester, Alignment, ExPASy, BLAST)
Laboratory's policy on reporting novel variations Help
Centogene has a common practice to report all variants found in genetic testing, including novel and previously reported variants. A number of criteria are used to support a variant as being potentially disease-causing, including segregation with disease status in other affected family members, absence from a control population, and location … View more
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Category:
FDA exercises enforcement discretion
Additional Information
Clinical resources:
Molecular resources:
Practice guidelines:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.